MarDee Haring-Layton - 26 Jan 2024 Form 3 Insider Report for Dare Bioscience, Inc. (DARE)

Role
Chief Accounting Officer
Signature
/s/ MarDee Haring-Layton
Issuer symbol
DARE
Transactions as of
26 Jan 2024
Net transactions value
$0
Form type
3
Filing time
29 Jan 2024, 16:18:34 UTC
Next filing
14 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DARE Employee Stock Option (right to buy) 26 Jan 2024 Common stock 3,500 $2.37 Direct F1
holding DARE Employee Stock Option (right to buy) 26 Jan 2024 Common stock 30,000 $1.01 Direct F1
holding DARE Employee Stock Option (right to buy) 26 Jan 2024 Common stock 35,000 $0.7590 Direct F1
holding DARE Employee Stock Option (right to buy) 26 Jan 2024 Common stock 25,000 $1.03 Direct F1
holding DARE Employee Stock Option (right to buy) 26 Jan 2024 Common stock 52,000 $2.59 Direct F1
holding DARE Employee Stock Option (right to buy) 26 Jan 2024 Common stock 42,000 $1.59 Direct F1
holding DARE Employee Stock Option (right to buy) 26 Jan 2024 Common stock 80,000 $1.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer.